Cas 635702-64-6 Pazopanib hydrochloride GW786034 HCl Inhibitor
Cas 635702-64-6 Pazopanib hydrochloride GW786034 HCl Inhibitor
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:Pazopanib HCl (GW786034 HCl) |
Purity:99% min |
|
CAS NO:635702-64-6 |
Solubility:DMSO10 mg/mL (21.10 mM; Need ultrasonic) |
|
Molecular Formula:C21H23N7O2S.HCl |
Package:Packaging according to customer requirements. |
|
Molecular Weight:473.98 |
Storage:Store at -20℃ |
Quality control
COA
Remarks
Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces autophagic Type II cell death.
In vitro:
Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1g/mL of Pazopanib and is completely abolished at 5g/mL.
Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability.
Related Prodcuts:
Sorafenib; Cabozantinib; Cabozantinib malate; Ponatinib; Axitinib; Vandetanib; Nintedanib; Regorafenib; Pazopanib; Cediranib; Dovitinib; Lenvatinib; Tivozanib; Sorafenib Tosylate; Sunitinib Malate
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.